With Congress in recess this week, we provide a status update on top health issues, including gun violence, mental health, COVID-19 and public health, health care costs, and Food and Drug Administration (FDA) user fees, as well as government funding. Overall, lawmakers have made some progress, with several marked-up bills awaiting floor votes. When Congress returns next week, lawmakers will... Read More
WHG - Weekly, May 23-27
On Saturday, President Biden signed a $40 billion aid package for Ukraine (H.R. 7691). Congressional leaders did not include emergency supplemental funding for COVID-19 out of concern that doing so would delay Ukrainian aid. Instead, they plan to advance the COVID funding bill separately, though the timing of the vote is unclear. House votes are not scheduled until June 7... Read More
WHG - Weekly, May 16-20
With the COVID-19 public health emergency (PHE) declaration currently set to end on July 15, today is the deadline for the Department of Health and Human Services (HHS) to provide states at least 60 days’ notice that the PHE will expire or terminate. On the congressional front, several committees will convene hearings on various topics, including mental health, fiscal year... Read More
WHG - Weekly, May 9-13
This week, congressional committees will convene hearings on top priorities, including the President’s fiscal year (FY) 2023 budget request, health of older adults, and mental health. Today, Senate Majority Leader Chuck Schumer (D-NY) is expected to tee up a Wednesday vote on the Women’s Health Protection Act (WHPA) of 2022 (S. 4132), which would prohibit government restrictions on the provision... Read More
WHG - Weekly, May 2-6
The House is in recess this week, but the Senate will push forward with their spring agenda, though mostly focused on energy and environmental issues. Appropriations hearings will continue with Department of Energy (DOE) Secretary Jennifer Granholm and Department of Transportation (DOT) Secretary Pete Buttigieg testifying on the fiscal 2023 budget proposal. Meanwhile, the Senate Environment and Public Works Committee... Read More
WHG - Weekly, April 25-29
Congress returns this week after a two-week spring recess. At the top of the agenda will be a push to pass the $10 billion bipartisan COVID-19 supplemental package that was negotiated just prior to leaving town earlier this month. The package was pulled by leadership just prior to recess due to Republicans demanding a vote on reinstating the Title 42... Read More
WHG - Weekly, April 18-22
Congress remains in recess and will return next week. In the meantime, we look ahead to anticipated regulations from the Biden Administration and key comment deadlines. The fiscal year (FY) 2023 inpatient prospective payment system (IPPS) proposed rule, which has cleared review at the Office of Management and Budget (OMB), is expected imminently this week. As part of the Biden... Read More
WHG - Weekly, April 11-15
With Congress in recess for the next two weeks, we look ahead to what happens to the different flexibilities put in place during the COVID-19 public health emergency (PHE) when the emergency declaration ends. A path for the bipartisan $10 billion COVID-19 supplemental bill, on hold due to disputes over the “Title 42” policy, is likely to remain uncertain until... Read More
WHG - Tracker of COVID-19 PHE Flexibilities
Wynne Health Group (WHG) has compiled a chart that delineates a comprehensive set of temporary flexibilities pursuant to the COVID-19 public health emergency (PHE). Under current PHE conditions, the U.S. Department of Health and Human Services (HHS) is authorized under section 1135 of the Social Security Act to waive a range of Medicare and Medicaid requirements as a means for... Read More
WHG - Overview of the Pharmacy Benefit Manager Regulatory and Legislative Landscape
While legislative momentum for drug pricing reform has waned since the Build Back Better (BBB) Act stalled, regulators and legislators have continued to focus on pharmacy benefit managers (PBMs) and their role in the pharmaceutical supply chain. As this recent attention has been spread across different agencies and between the federal and state legislatures, the Wynne Health Group has compiled... Read More
WHG - Weekly, April 4-8
Ahead of the two-week congressional recess, the Senate will have a busy week continuing to negotiate a bipartisan COVID-19 supplemental package and advancing the nomination of Ketanji Brown Jackson to the U.S. Supreme Court. Tomorrow, former President Barack Obama will return to the White House for an event celebrating the Affordable Care Act (ACA). President Biden is also expected to... Read More
WHG - Weekly, March 28-April 1
Today, President Biden is slated to release his fiscal year (FY) 2023 budget request, officially kicking off the appropriations process for the next fiscal year beginning on October 1, 2022. Throughout the week, committees in both chambers will hold hearings on various health policy priorities, including universal health coverage, behavioral health care, Food and Drug Administration (FDA) user fees, and... Read More
WHG - Weekly, March 21-25
This week, the Senate Judiciary Committee will hold four days of confirmation hearings on President Biden’s nomination of Ketanji Brown Jackson to serve on the Supreme Court of the United States. Last year, three Republican senators (Sens. Susan Collins (R-ME), Lisa Murkowski (R-AK), and Lindsey Graham (R-SC)) voted with Democrats to confirm Judge Jackson to the U.S. Court of Appeals... Read More
WHG - Weekly, March 14-18
This week, House leaders plan to vote on a standalone $15.6 billion COVID supplemental package (H.R. 7007) that was pulled from the fiscal year (FY) 2022 appropriations omnibus due to pushback from some Democrats over the offsets. Nearly identical to the original version, this new bill includes $9.85 billion to procure therapeutics and vaccines, $750 million to develop vaccines against... Read More
WHG - Possible CMMI Action on Drug Pricing
Following the collapse of the Build Back Better Act (BBBA), it remains unclear whether Congress will pass drug pricing legislation. While it is still possible for Congress to act on separate components of the BBBA (including drug pricing) via reconciliation, there is less insight into how exactly Democrats plan to move forward on these legislative priorities. It has remained WHG’s... Read More
WHG - Weekly, March 7-11
The deadline to fund the government for fiscal year (FY) 2022 is this Friday, March 11. Democrats are pushing to include COVID-19 supplemental funding in the FY 2022 appropriations omnibus, along with Ukraine assistance. “Democrats have made a reasonable global offer to Republicans and it is my hope that we will reach an agreement very soon so that we can... Read More
WHG - Weekly, February 28-March 4
This week’s main event is President Biden’s first State of the Union address tomorrow evening. While the President’s remarks will have a significant focus on national security, we anticipate his speech will also touch on the Biden Administration’s COVID-19 response and health care priorities. Biden may provide some direction to lawmakers on which health policies of the Build Back Better... Read More
WHG - Weekly, February 22-25
With Congress in recess this week, we look ahead to what is underway on the administrative front – including changes to electronic prior authorization, Medicare payment updates, Medicare Advantage (MA) and Part D Advance Notice, and modifications to Medicare enrollment. Additionally, we highlight key activities and dates related to the unwinding of the Medicaid continuous coverage requirement... Read More
WHG - Weekly, February 14-18
Senate Votes A third continuing resolution (CR) appears to be the charm for fiscal year (FY) 2022 appropriations. On the heels of an agreed-to “bipartisan appropriations framework,” the Senate is expected to pass the House-approved (272-162) stopgap funding extension before the current CR expires on February 18. Lawmakers will then have until March 11 to negotiate and finalize all 12... Read More
WHG - Roundup of Recent Telehealth Policy
Federal attention on telehealth continues to mount. This is true especially as uncertainty builds around when the COVID-19 public health emergency (PHE) will end, which would mark the end of many telehealth flexibilities absent further congressional action (though the Administration may allow any flexibilities to persist for up to an additional 60 days following the end of the PHE). The... Read More
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 19
- Next Page »